FDA Approves Inhaled Insulin For Children Ages 6 Plus

Children with diabetes now have a needle-free delivery option for insulin, provided they do not have asthma or a history of smoking.

Updated on Oct. 26, 2026 in Asthma

A modern, compact handheld medical inhalation device resting on a sterile, white surface, used for pediatric diabetes management. — The FDA has authorized the use of inhaled insulin for children ages 6 and older, offering a new, non-invasive method for managing pediatric diabetes. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical technology is the most important factor in improving quality of life?

In late May 2026, the FDA expanded the approval of the inhaled insulin Afrezza for children as young as 6 years old. This needle-free option aims to improve diabetes management for pediatric patients by simplifying insulin delivery.

Why it matters

By eliminating the need for traditional injections, this delivery method can help reduce pain and stigma associated with diabetes care for children. The approval provides a new management alternative for families, though it does not replace the need for basal insulin.

The FDA approved Afrezza for pediatric use in May 2026 based on regulatory review of the delivery device, which offers cartridges in 4, 8, or 12-unit strengths. Future accessibility and insurance reimbursement policies for children remain under investigation.

The players

FDA

The United States Food and Drug Administration is the federal agency responsible for protecting public health by regulating pharmaceuticals and medical devices.

The details

Afrezza uses a handheld device to deliver insulin in powder form directly into the lungs, where it enters the bloodstream in under one minute. While it offers a non-invasive alternative to needles, the drug is strictly contraindicated for individuals who smoke, vape, or have asthma due to potential respiratory side effects. Common side effects reported with the therapy include cough and dry mouth.

The FDA approved the expanded use of the insulin inhaler in May 2026.
Financial assistance programs for the medication are available through December 2026.

Health Landscape

This development marks a shift in the pediatric diabetes treatment landscape by providing an inhaled alternative to traditional injectable insulin. It follows the standard FDA pediatric regulatory approval process designed to expand safe, age-appropriate medical management options.

Parents and caregivers should note that this treatment is not suitable for children with asthma, nor for those who are exposed to smoking or vaping. Discuss with your child's endocrinologist whether inhaled insulin is a safe and appropriate component of their diabetes care plan.

The takeaway

The availability of inhaled insulin represents a significant advancement in reducing the physical burden of daily diabetes care for children. If you are exploring new management options, prioritize a conversation with your physician to evaluate if this non-injectable method aligns with your child's health needs.